Partner
For more than 25 years, Scott has represented pharmaceutical companies on matters involving blockbuster drugs such as Zyprexa®, Evista®, Strattera®, and Enbrel®. He was recognized in Managing IP Handbook as "a fantastic writer, someone who can take sometimes very abstract scientific principles and truly abstract intellectual property principles, and reduce that to a written document that is clear, concise and understandable." He is also listed in LMG Life Sciences as an Intellectual Property: Life Sciences Star and recognized for his contributions in the fields of General Patent Litigation and Hatch-Waxman Patent Litigation.
Scott regularly publishes and lectures on various issues of patent law. He has been an adjunct professor at Howard University School of Law since 2007, teaching patent law and public policy courses. Scott was Finnegan's Partner-in-Charge of Diversity, Equity, and Inclusion, and he previously served on the firm's management committee and as the hiring partner for the firm's Washington, D.C., and Reston offices.
Scott has been a faculty member of the National Institute of Trial Advocacy's Building Trial Skills and Deposition Skills programs and was an advisory board member of Bloomberg BNA's Pharmaceutical Law and Industry Report. He currently serves on the board of directors for the Washington Lawyers' Committee for Civil Rights and Urban Affairs.
Eli Lilly and Company v. Genentech, Inc.
Lead counsel for petitioner Eli Lilly and Company in post-grant review proceeding before PTAB relating to patent on IL-17A/F antibodies that had been asserted against Lilly’s blockbuster Taltz® pharmaceutical. Successfully obtained institution of PGR and judgment in favor of petitioner.
PGR2019-00043, PTAB, Judges Mitchell, Paulraj, Cotta
3:18-cv-01518, S.D. Cal., Judge Sammartino
Alzheimer's Institute of America, Inc. v. Avid Radiopharmaceuticals
Represented Avid in suit concerning amyloid beta technology and its use in animal models in searching for drugs to treat Alzheimer’s disease. Obtained jury verdict for Avid on issue of inventorship and patent ownership in 2012; affirmed by the Federal Circuit in 2013. Also obtained a finding of exceptional case and secured judgment of $3.9 million in attorneys’ fees to Avid. The trial disposed of a series of suits by the AIA against numerous companies involved in scientific research relating to Alzheimer’s disease.
2:10-cv-06908, E.D. Pa., Judges Angell, Savage, Cohen (Special Master)
13-1544, 16-2647, Fed. Cir., Judges Hughes, Lourie, Moore, Newman, Plager
Alzheimer's Institute of America, Inc. v. Eli Lilly and Company
Represented Eli Lilly in suit concerning technology used in searching for drugs to treat Alzheimer’s disease. Obtained dismissal with prejudice based on lack of standing. Also obtained a finding of exceptional case and secured judgment of $4.4 million in attorneys’ fees to Lilly.
3:10-cv-00482, N.D. Cal., Judges Breyer, James, Laporte
Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc.
Represented Eli Lilly and Company in Hatch-Waxman patent litigation relating to osteoporosis drug Forteo®.
1:16-cv-00596, S.D. Ind., Judges Pratt, Brookman
Lannett Holdings, Inc. v. AstraZeneca AB
Represented patent owner AstraZeneca in two IPRs relating to Zomig® Nasal Spray, leading to non-institution decisions in both proceedings.
IPR2015-01629, -01630, PTAB
Eli Lilly and Company v. Actavis Elizabeth LLC
10-1500, -1520, -1521, -1522, -1523, -1524, Fed. Cir., Judges Lourie, Newman
2:07-cv-03770, D.N.J., Judges Cavanaugh, Dickson, Falk
Podcasts
California Privacy Protection Agency Enforcement Investigation California Privacy Protection Agency Enforcement Investigation
September 25, 2023
Event
2023 FCBA Bench & Bar Conference 2023 FCBA Bench & Bar Conference
June 28 - July 1, 2023
Colorado Springs
Event
Careers in IP Law: A World of Possibilities Careers in IP Law: A World of Possibilities
March 1, 2023
Virtual
Event
4th Annual HBCU Tech Law Summit & 19th Annual IP and Social Justice CLE Seminar 4th Annual HBCU Tech Law Summit & 19th Annual IP and Social Justice CLE Seminar
March 3-4, 2022
Virtual
Event
Careers in IP Law: A world of possibilities Careers in IP Law: A world of possibilities
February 16, 2022
Virtual
Articles
A Catalyst for Action A Catalyst for Action
June 10, 2021
World Intellectual Property Review“Scott Burwell is another standout in the litigation group…”
LMG Life Sciences
“Scott Burwell is another standout in the litigation group…”
LMG Life Sciences
Press Release
Registration Open for Finnegan’s 2024 IP University Program Registration Open for Finnegan’s 2024 IP University Program
December 11, 2023
Commentary
How I Made It to Law Firm Leadership: 'Devote Time to Initiatives That Improve the Firm' How I Made It to Law Firm Leadership: 'Devote Time to Initiatives That Improve the Firm'
November 13, 2023
Law.comAnnouncement
Elizabeth Ferrill Recognized by World IP Review as 2023 Diversity Champion Elizabeth Ferrill Recognized by World IP Review as 2023 Diversity Champion
October 16, 2023
World Intellectual Property ReviewAward/Ranking
Finnegan Upholds Tier 1 Marks in 2023 LMG Life Sciences Rankings Finnegan Upholds Tier 1 Marks in 2023 LMG Life Sciences Rankings
September 21, 2023
LMG Life SciencesPress Release
Finnegan Continues to Hold Top-Tier LMG Life Sciences 2022 Rankings Finnegan Continues to Hold Top-Tier LMG Life Sciences 2022 Rankings
September 22, 2022
LMG Life SciencesDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.